Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An announcement from GlaxoSmithKline Pharmaceuticals Limited ( (IN:GLAXO) ) is now available.
GlaxoSmithKline Pharmaceuticals Limited has announced a leadership change in its finance function, appointing Ronojit Biswas as Whole-Time Director and Chief Financial Officer for a three-year term starting 1 April 2026. Biswas, a long-serving GSK executive, brings over 25 years of international finance experience across markets such as India, Vietnam, Singapore, Brazil and the UK, reinforcing the company’s focus on experienced internal talent for critical roles.
He succeeds current CFO and Whole-Time Director Juby Chandy, who will step down from these roles on 11 March 2026 to take up a new position leading APAC Finance within the wider GSK group. The transition underscores GSK’s emphasis on continuity in financial stewardship, governance and strategic execution, while signalling the importance of the India business within the group’s regional and global leadership structure.
More about GlaxoSmithKline Pharmaceuticals Limited
GlaxoSmithKline Pharmaceuticals Limited is an India-based pharmaceutical company focused on developing and marketing prescription medicines and healthcare products. Operating as part of the global GSK group, it serves the Indian market with a portfolio spanning key therapeutic areas while aligning with the multinational’s broader strategic and governance standards.
Average Trading Volume: 4,882
Technical Sentiment Signal: Buy
Current Market Cap: 435.4B INR
For a thorough assessment of GLAXO stock, go to TipRanks’ Stock Analysis page.